World News: 09:42 GMT Thursday 6th December 2018. [Research and Markets via Globe Newswire via SPi World News]
Dublin, Dec. 06, 2018 (GLOBE NEWSWIRE) -- The report has been added to offering.
The anti-obesity drugs market is projected to register a CAGR of almost 8% by 2023.
The research on drugs that target obesity and type 2 diabetes mellitus to gain traction in the market. The global epidemic obesity and type 2 diabetes is increasing. This demands for increasing focus on the drugs that can control obesity and diabetes.
The market appears to be concentrated and with the presence of few companies including Eisai and Novo Nordisk the competitive environment is quite intense. Factors such as the increase in childhood obesity incidence and the use of implantable neuroregulatory devices for treating obesity, will provide considerable growth opportunities to anti-obesity drugs manufactures.
With the presence of a considerable number of companies, this market appears to be fragmented. This market to witness the presence of a few international and regional anti-obesity drug companies who offer obesity treatment drugs for mechanism such as centrally-acting and peripherally-acting anti-obesity drugs.
For more information about this report visit
Research and Markets also offers services providing focused, comprehensive and tailored research.
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Anti-Obesity Drugs
Globe Newswire: 09:42 GMT Thursday 6th December 2018
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.